cagrilintide semaglutide combination cagrisema phase 3 2025 results Novo Nordisk's stock drops despite hitting goal of III trial Another obesity contender just raised
Another obesity contender just raised the stakes. Novo Nordisk's CagriSema combination delivered around 20% mean weight loss in a large trial. The formula combines semaglutide with cagrilintide, giving the body multiple appetite control Cagrilintide and Semaglutide: CagriSema Weight Loss Guide SeekPeptides CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure Nature Metabolism Novo Nordisk's CagriSema outperforms Ozempic in Phase III trial
Pay in 4 interest-free payments of $6.20 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8


